Screener
Bio-Techne TECH Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Bio-Techne in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Bio-Techne’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q3 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056302
| Line item | Nine Months Ended / March 31, 2026 | Nine Months Ended / March 31, 2025 |
|---|---|---|
| Depreciation and amortization | 73,218 | 82,792 |
| Costs recognized on sale of acquired inventory | — | 554 |
| Deferred income taxes | 8,045 | (18,825) |
| Stock-based compensation expense | 36,135 | 36,283 |
| (Gain) Loss on equity method investment | 335 | 169 |
| (Gain) Loss on investments | 2,334 | — |
| Asset impairment restructuring | 3,253 | 9,961 |
| Leases, net | (2,619) | 502 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Bio-Techne's stock-based comp?
- Bio-Techne (TECH) reported stock-based comp of $10.5M in Q1 2026.
- How has Bio-Techne's stock-based comp changed year-over-year?
- Bio-Techne's stock-based comp decreased by 7.9% year-over-year, from $11.39M to $10.5M.
- What is the long-term trend for Bio-Techne's stock-based comp?
- Over 3 years (2022 to 2025), Bio-Techne's stock-based comp has grown at a -1.1% compound annual growth rate (CAGR), from $42.18M to $40.83M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Bio-Techne's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude